---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-22-000990"
form_type: "8-K"
ticker: "ENTXW"
cik: "0001638097"
company_name: "Entera Bio Ltd."
filed_at: "2022-03-08T23:59:59+00:00"
generated_at: "2026-06-27T00:48:42.196850+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Entera Bio reports $12.2M net loss for 2021; guides FY2022 operating loss of $25-30M; EB613 Phase 3 trial in 2022

## Summary
- Revenue $571k in 2021 vs $365k in 2020; net loss $12.2M ($0.47 per share) vs $11.2M ($0.67 per share).
- Cash $24.9M at Dec 31, 2021; $21.7M at Mar 1, 2022; expects FY2022 operating loss $25-30M.
- EB613 (osteoporosis) Phase 3 pivotal trial expected to start in 2022 after positive FDA End of Phase 2 meeting.
- EB612 (hypoparathyroidism) improved formulation; next clinical trial planned in 2022; Orphan Drug status FDA and EMA.
- Engaged Torreya Capital as financial advisor for non-dilutive strategic alliances for EB613.

## SEC filing metadata
- accession: 0001178913-22-000990
- form_type: 8-K
- ticker: ENTXW
- cik: 0001638097
- company_name: Entera Bio Ltd.
- filed_at: 2022-03-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1638097/000117891322000990/0001178913-22-000990-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1638097/000117891322000990/form8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-22-000990
- JSON: https://secwatch.observer/filing/0001178913-22-000990.json
- Plain text: https://secwatch.observer/filing/0001178913-22-000990.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.